Edwards Lifesciences - מכפיל P/S עתידי EW

Edwards Lifesciences' leadership in the development of cardiac systems and its robust R&D drive the price action. On the GURU.Markets platform, the company's expected P/S illustrates market expectations, where the value 4.50 describes the current level. Simultaneously, the business is implementing strict raw material certification to reduce toxic emissions and is transitioning to eco-packaging using renewable energy at its plants.

The market values Edwards Lifesciences (EW) as a high-tech leader with premium growth potential. The company's expected P/S ratio compares current market capitalization with projected revenue, determining the fair value of future sales flows. This chart confirms the valuation's resilience, as inelastic demand for unique TAVR systems allows the business to maintain high pricing power, transforming the asset into a defensive tool with a high-quality fundamental profile.